UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Enlarge Text
Click to increase the text size. Restore Text
Click to restore original text size. Reduce Text
Click to decrease the text size.


Decrease the text size \| Restore text size \| Increase the text size

Cefazolin

In Vitro Substrates

* denotes drugs that can potentially be used for in vivo (clinical) studies of the designated transporter

Transporter	Synonyms	Km (μM)	Cell System	Reference
SLCO1B3	OATP1B3, OATP8	3.89	oocytes-OATP1B3	Nakakariya, 2008
SLCO1B1	OATP1B1, OATP-C, OATP2, LST-1	20.8	OATP1B1-expressing oocytes	Nakakariya, 2008

* denotes drugs that can potentially be used for in vivo (clinical) studies of the designated transporter

Transporter	Synonyms	Inhibitor	IC50 (μM)	Ki (μM)	Substrate used	Cell System	Reference
SLC22A5	OCTN2	Cefazolin		6740	L-carnitine	L6-hOCTN2	Todesco, 2008
SLC22A8	OAT3	Cefazolin	650		Pemetrexed	HEK-OAT3	Kurata, 2014
SLC22A11	OAT4	Cefazolin		1740	Prostaglandin F2-alpha	S2-OAT4	Khamdang, 2003
SLC22A6	OAT1	Cefazolin		180	Prostaglandin F2-alpha	S2-OAT1	Khamdang, 2003
SLC22A8	OAT3	Cefazolin		550	Prostaglandin F2-alpha	S2-OAT3	Khamdang, 2003
SLC22A8	OAT3	Cefazolin	99		Relebactam	MDCKII-OAT3	Chan, 2019
ABCB11	BSEP	Cefazolin	>133		Taurocholate	Sf9 cell membrane vesicles	Morgan, 2013

No drug-drug interaction information.